Only recently this concept has been proven ultimately successful in the clinic for the first time, with the FDA approval of the PARP inhibitor Olaparib as monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy [11]. This evidence concerns the gene PARP1 and ovarian carcinoma.